Literature DB >> 22465309

Exendin-4 decreases amphetamine-induced locomotor activity.

Kevin Erreger1, Adeola R Davis, Amanda M Poe, Nigel H Greig, Gregg D Stanwood, Aurelio Galli.   

Abstract

Glucagon-like peptide-1 (GLP-1) is released in response to nutrient ingestion and is a regulator of energy metabolism and consummatory behaviors through both peripheral and central mechanisms. The GLP-1 receptor (GLP-1R) is widely distributed in the central nervous system, however little is known about how GLP-1Rs regulate ambulatory behavior. The abused psychostimulant amphetamine (AMPH) promotes behavioral locomotor activity primarily by inducing the release of the neurotransmitter dopamine. Here, we identify the GLP-1R agonist exendin-4 (Ex-4) as a modulator of behavioral activation by AMPH. We report that in rats a single acute administration of Ex-4 decreases both basal locomotor activity as well as AMPH-induced locomotor activity. Ex-4 did not induce behavioral responses reflecting anxiety or aversion. Our findings implicate GLP-1R signaling as a novel modulator of psychostimulant-induced behavior and therefore a potential therapeutic target for psychostimulant abuse.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22465309      PMCID: PMC3348974          DOI: 10.1016/j.physbeh.2012.03.014

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  65 in total

Review 1.  Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure.

Authors:  Linda Rinaman
Journal:  Brain Res       Date:  2010-03-27       Impact factor: 3.252

2.  GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.

Authors:  Manuel Gil-Lozano; Diego Pérez-Tilve; Mayte Alvarez-Crespo; Aurelio Martís; Ana M Fernandez; Pablo A F Catalina; Lucas C Gonzalez-Matias; Federico Mallo
Journal:  Endocrinology       Date:  2010-04-02       Impact factor: 4.736

Review 3.  GLP-1 and energy balance: an integrated model of short-term and long-term control.

Authors:  Jason G Barrera; Darleen A Sandoval; David A D'Alessio; Randy J Seeley
Journal:  Nat Rev Endocrinol       Date:  2011-06-07       Impact factor: 43.330

4.  Psychological and quality of life changes in patients using GLP-1 analogues.

Authors:  Paul Grant; David Lipscomb; John Quin
Journal:  J Diabetes Complications       Date:  2011-05-20       Impact factor: 2.852

5.  A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats.

Authors:  C T Peters; Y H Choi; P L Brubaker; G H Anderson
Journal:  J Nutr       Date:  2001-08       Impact factor: 4.798

Review 6.  Modulation of the mesolimbic dopamine system by leptin.

Authors:  Darren M Opland; Gina M Leinninger; Martin G Myers
Journal:  Brain Res       Date:  2010-04-22       Impact factor: 3.252

Review 7.  Glucagon-like peptide-1, glucose homeostasis and diabetes.

Authors:  Jens J Holst; Carolyn F Deacon; Tina Vilsbøll; Thure Krarup; Sten Madsbad
Journal:  Trends Mol Med       Date:  2008-03-18       Impact factor: 11.951

8.  Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation.

Authors:  Matthew R Hayes; Karolina P Skibicka; Harvey J Grill
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

9.  Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.

Authors:  Claude Knauf; Patrice D Cani; Afifa Ait-Belgnaoui; Alexandre Benani; Cédric Dray; Cendrine Cabou; André Colom; Marc Uldry; Sophie Rastrelli; Eric Sabatier; Natacha Godet; Aurélie Waget; Luc Pénicaud; Philippe Valet; Rémy Burcelin
Journal:  Endocrinology       Date:  2008-06-12       Impact factor: 4.736

10.  Preproglucagon neurons project widely to autonomic control areas in the mouse brain.

Authors:  I J Llewellyn-Smith; F Reimann; F M Gribble; S Trapp
Journal:  Neuroscience       Date:  2011-02-15       Impact factor: 3.590

View more
  36 in total

1.  Pre-existing differences in motivation for food and sensitivity to cocaine-induced locomotion in obesity-prone rats.

Authors:  Peter J Vollbrecht; Cameron W Nobile; Aaron M Chadderdon; Emily M Jutkiewicz; Carrie R Ferrario
Journal:  Physiol Behav       Date:  2015-09-28

2.  Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

3.  Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior.

Authors:  Anne E Harasta; John M Power; Georg von Jonquieres; Tim Karl; Daniel J Drucker; Gary D Housley; Miriam Schneider; Matthias Klugmann
Journal:  Neuropsychopharmacology       Date:  2015-02-11       Impact factor: 7.853

4.  GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.

Authors:  Ajaykumar N Sharma; Sagar S Ligade; Jay N Sharma; Praveen Shukla; Khalid M Elased; James B Lucot
Journal:  Metab Brain Dis       Date:  2014-07-15       Impact factor: 3.584

Review 5.  PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.

Authors:  Stefan Trapp; Simon C Cork
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-19       Impact factor: 3.619

6.  The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.

Authors:  Gunnar Sørensen; India A Reddy; Pia Weikop; Devon L Graham; Gregg D Stanwood; Gitta Wortwein; Aurelio Galli; Anders Fink-Jensen
Journal:  Physiol Behav       Date:  2015-06-11

7.  Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice.

Authors:  Lital Rachmany; David Tweedie; Yazhou Li; Vardit Rubovitch; Harold W Holloway; Jonathan Miller; Barry J Hoffer; Nigel H Greig; Chaim G Pick
Journal:  Age (Dordr)       Date:  2012-08-15

Review 8.  Obesity and addiction: neurobiological overlaps.

Authors:  N D Volkow; G-J Wang; D Tomasi; R D Baler
Journal:  Obes Rev       Date:  2012-09-27       Impact factor: 9.213

9.  Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.

Authors:  Timothy L Ramsey; Mark D Brennan
Journal:  Schizophr Res       Date:  2014-10-18       Impact factor: 4.939

10.  The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

Authors:  Anna Secher; Jacob Jelsing; Arian F Baquero; Jacob Hecksher-Sørensen; Michael A Cowley; Louise S Dalbøge; Gitte Hansen; Kevin L Grove; Charles Pyke; Kirsten Raun; Lauge Schäffer; Mads Tang-Christensen; Saurabh Verma; Brent M Witgen; Niels Vrang; Lotte Bjerre Knudsen
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.